Search Results

Centrexion Therapeutics Corporation, a biotechnology company focused on developing and commercializing non-opioid, non-addictive chronic pain drugs and in-licensing undervalued mid-stage drug candidates across multiple target therapeutic areas, today announced that it has raised $40.5 million of cash via: Convertible security investments from Lilly and Exome Asset Management – each a new investor in Centrexion; Collaboration-related investment from

Excision BioTherapeutics, Inc., a clinical-stage biotechnology company developing CRISPR-based therapies designed to cure viral infectious diseases, today announced the appointment of Jeffrey B. Kindler, former Chairman and Chief Executive Officer (CEO) of Pfizer and current CEO of Centrexion Therapeutics, to its Board of Directors.

Eli Lilly announced it has inked a license agreement with Centrexion Therapeutics to acquire the exclusive global rights to CNTX-0290.

Eli Lilly and Company announced a license agreement to acquire the exclusive worldwide rights for CNTX-0290 from Centrexion Therapeutics Corporation, a company focused on developing non-opioid, non-addictive therapeutics for the treatment of chronic pain.

Centrexion Therapeutics Corporation announced that Nick Harvey has been appointed Chief Financial Officer of the company.

Centrexion Therapeutics Corporation today announced that Andrew Partridge has been appointed Executive Vice President, Chief Commercial Officer of the company.

Centrexion Therapeutics Corporation, a company focused on developing non-opioid, non-addictive therapies for the treatment of chronic pain, today announced it will present posters on CNTX-4975 at the 2019 American College of Rheumatology (ACR) Annual Meeting Conference taking place November 8-13, 2019 in Atlanta, Georgia and at the 2019 American Academy of Physical Medicine and Rehabilitation (AAPM&R) Annual Assembly taking place November 14-17, 2019 in San Antonio, Texas.

CNTX-4975, Centrexion’s Phase 3 ready lead therapy, is a synthetic, ultra-pure injection of trans-capsaicin designed to be injected directly into the painful joint to provide rapid and durable pain relief.

Centrexion Therapeutics Corporation, a company focused on developing non-opioid, non-addictive therapeutics for the treatment of chronic pain (the “Company”), announced today that it will present updated safety and efficacy data of CNTX-4975, the Company’s lead therapeutic candidate, at the 12th Annual PAINWeek National Conference

Centrexion closed on a Series D financing worth $67M to develop its knee osteoarthritis drug in Phase III.